Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for women's cancers. Co. is focused on developing therapies for the treatment of breast cancer. Co.'s wholly owned, primary product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist and a selective ER degrader. Co. is evaluating OP-1250 in a dose escalation and expansion trial for the treatment of ER-positive, human epidermal growth factor receptor 2-negative breast cancer. The OLMA YTD return is shown above.
The YTD Return on the OLMA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether OLMA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OLMA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|